Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries
View as:

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05205252 Org: User:
Start: 12/22/21 End: 07/05/23 Due: 07/05/24

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02601937 Org: User:
Start: 01/07/16 End: 10/22/21 Due: 10/22/22

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT01897571 Org: User:
Start: 06/13/13 End: 11/02/21 Due: 11/02/22

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT03028103 Org: User:
Start: 03/27/17 End: 11/29/19 Due: 11/29/20

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04204941 Org: User:
Start: 12/19/19 End: 01/01/30 Due: 01/01/31

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Phase: N/A Priority: Normal
NCT ID: NCT04241835 Org: User:
Start: 01/15/20 End: 12/31/25 Due: 12/31/26

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Phase: N/A Priority: Normal
NCT ID: NCT04224493 Org: User:
Start: 06/11/20 End: 03/01/29 Due: 03/01/30

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02601950 Org: User:
Start: 12/22/15 End: 02/26/24 Due: 02/26/25

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05121103 Org: User:
Start: 05/31/22 End: 04/30/24 Due: 04/30/25

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04179864 Org: User:
Start: 11/18/19 End: 11/04/24 Due: 11/04/25

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT02860286 Org: User:
Start: 07/31/16 End: 05/31/19 Due: 05/31/20

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

Phase: N/A Priority: Normal
NCT ID: NCT01684150 Org: User:
Start: 09/30/12 End: 02/29/16 Due: 02/28/17

Epithelioid Sarcoma Natural History Study

Phase: N/A Priority: Normal
NCT ID: NCT03837678 Org: User:
Start: 06/04/18 End: 09/02/21 Due: 09/02/22

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT02875548 Org: User:
Start: 08/30/16 End: 11/03/25 Due: 11/03/26

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

Phase: N/A Priority: Normal
NCT ID: NCT02141828 Org: User:
Start: 05/31/14 End: 06/30/16 Due: 06/30/17

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03874455 Org: User:
Start: - End: - Due: -

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03010982 Org: User:
Start: 06/20/18 End: 01/08/19 Due: 01/08/20

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06068881 Org: User:
Start: 09/02/25 End: 04/06/29 Due: 04/06/30

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04225429 Org: User:
Start: - End: - Due: -

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Phase: N/A Priority: Normal
NCT ID: NCT04537715 Org: User:
Start: 04/23/20 End: 04/03/23 Due: 04/03/24

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04762160 Org: User:
Start: 12/15/20 End: 03/22/22 Due: 03/22/23